CA 125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis

References

• Braunwald E. Heart Disease. Philadelphia: W.B. Saunders Company; 2001:635
   Google Scholar
• Foley R, Parfrey P, Hefferton D, Kent G, Murray D, Barre P. Advance prediction of early death in patients starting maintenance dialysis. Am J Kidney Dis. 1994;23:836–845
   PubMed Web of Science ®Google Scholar
• Churchill D, Taylor D, Cook R, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992;19:214–234
   PubMed Web of Science ®Google Scholar
• Foley R, Parfrey P, Harnett J, et al. Clinical end echocardiographic disease in patients starting endstage renal disease therapy. Kidney Int. 1995;47:186–192
   PubMed Web of Science ®Google Scholar
• Foley R. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16:111–117
   PubMed Web of Science ®Google Scholar
• Harnett J, Foley R, Kent G, Barre P, Murray D, Parfrey P. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884–890
   PubMed Web of Science ®Google Scholar
• Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer. 1984;50:765–769
   PubMed Web of Science ®Google Scholar
• Klapdor R, Klapdor U, Bahlo M, et al. CA 125 in cancer of the digestive tract. Dtsch Med Wochenschr. 1984;109:1949–1954
   PubMedGoogle Scholar
• Camera A, Villa MR, Rocco S, et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement. Cancer. 2000;88:75–78
   PubMed Web of Science ®Google Scholar
• Zacharos ID, Efstathiou SP, Petreli E, et al. The prognostic significance of CA 125 in patients with non-Hodgkin’s lymphoma. Eur J Hematol. 2002;69:221–226
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril. 1986;45:630–634
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Bruix J, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379–1383
   PubMed Web of Science ®Google Scholar
• Halila H, Stenman UH, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer. 1986;57:1327–1329
   PubMed Web of Science ®Google Scholar
• Candocia SA, Locker GY. Elevated serum CA 125 secondary to tuberculous peritonitis. Cancer. 1993;72:2016–2018
   Google Scholar
• Seo T, Ikeda Y, Onaka H, et al. Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J. 1993;57:489–494
   Google Scholar
• Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J. 1999;137:1044–1049
   PubMed Web of Science ®Google Scholar
• D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. Relation to clinical severity hemodynamic and doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41:1805–1811
   PubMed Web of Science ®Google Scholar
• Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005;7:199–203
   PubMed Web of Science ®Google Scholar
• Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail. 2005;7:840–843
   PubMed Web of Science ®Google Scholar
• Kouris NT, Kontogianni DD, Papoulia EP, et al. Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure. Hellenic J Cardiol (Greece). 2006;47:269–274
   Google Scholar
• Antonini-Canterin F, Popescu BA, Popescu AC, et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol. 2008;128:406–412
   Google Scholar
• Wang AY, Sanderson JE. Current perspectives on diagnosis of heart failure in long-term dialysis patients. Am J Kidney Dis. 2011;57:308–319
   Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Echocardiogr. 2005;18:1440–1463
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277–1285
   PubMed Web of Science ®Google Scholar
• Arik N, Adam B, Akpolat T, Hasil K, Tabak S. Serum tumor markers in renal failure. Int Urol Nephrol. 1996;28:601–604
   PubMedGoogle Scholar
• Lye WC, Tambyah P, Leong SO, Lee EJ. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial. 1994;10:109–111
   PubMedGoogle Scholar
• Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron. 1991;57:183–186
   PubMed Web of Science ®Google Scholar
• Bastani B, Chu N. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Am J Nephrol. 1995;15:468–472
   Google Scholar
• Zeferos N, Digenis GE, Christophoraki M, et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron. 1991;59:618–620
   PubMed Web of Science ®Google Scholar
• Odagiri E, Jibiki K, Takeda M, et al. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA-125, CA-19-9 and CA-15-3 in uremic patients. Am J Nephrol. 1991;11:363–368
   Google Scholar
• Duman D, Palit F, Simsek E, et al. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail. 2008;10:556–559
   PubMedGoogle Scholar
• Vizzardi E, Nodari S, D’Aloia A, et al. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography. 2008;25:955–960
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol. 2011;149:80–82
   PubMed Web of Science ®Google Scholar
• Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer. 1987;59:213–217
   PubMed Web of Science ®Google Scholar
• Turk HM, Pekdemir H, Buyukberber S, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumor Biol. 2003;24:172–175
   PubMedGoogle Scholar
• Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999;1:309–312
   PubMedGoogle Scholar
• Blum A, Miller H. Role of cytokines in heart failure. Am Heart J. 1998;135:181–186
   PubMed Web of Science ®Google Scholar
• Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 2001;3:517–526
   PubMed Web of Science ®Google Scholar
• Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in pathophysiology of heart failure. J Am Col Cardiol. 2000;35:537–544
   PubMed Web of Science ®Google Scholar
• Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77:723–727
   PubMed Web of Science ®Google Scholar
• Kosar F, Varol E, Ileri M, Ayaz S, Hisar I, Kisacik H. Circulating cytokines and complements in chronic heart failure. Angiology. 1999;50:403–408
   Google Scholar
• Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241
   PubMed Web of Science ®Google Scholar
• MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997;79:1128–1131
   PubMed Web of Science ®Google Scholar
• Kosar F, Aksoy Y, Ozguntekin G, Ozeral I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2006;8:270–274
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Offner FA, Marth C, et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res. 1997;17:3129–3131
   PubMed Web of Science ®Google Scholar
• Kubonishi I, Bandobashi K, Murata N, et al. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Hematol. 1997;98:450–452
   PubMed Web of Science ®Google Scholar
• Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol. 1994;47:263–265
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Marth C, Offner FA, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–389
   Google Scholar
• Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23:551–562
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimbürger O, Wang T, et al. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis. 1999;34:1083–1088
   PubMedGoogle Scholar
• Sharma R, Bolger AP, Li W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol. 2003;92:188–193
   PubMedGoogle Scholar